Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Department of Computer Science and Engineering Southern University of Science and Technology 1088 Xueyuan Avenue, Nanshan District Shenzhen Guangdong 518055 China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Division of Epidemiology and Biostatistics School of Public Health University of Hong Kong Hong Kong Special Administrative Region, 21 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
Division of Infectious Diseases Department of Medicine LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 102 Pokfulam Road Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
COVID-19 pandemic has caused more than 6.6 million deaths globally. Tremendous efforts have been committed for the development of new and repurposed drugs for the treatment of COVID-19. Although diffe...
This review focuses on recent data from randomized trials and postmarketing real-world evidence for the treatment of mild to moderate disease in the outpatient setting and patients hospitalized for CO...
Treatment of COVID-19 should be personalized according to host characteristics, degree of severity and available treatment options....
There has been a profusion of trials for SARS CoV2 drugs. A review dating from May 2020 listed 115 medicines, most of which previously existed, having been investigated since the onset of the pandemic...
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS...
The cytokine storm (CS) triggered by coronavirus disease 2019 (COVID-19) has caused serious harm to health of humanity and huge economic burden to the world, and there is a lack of effective methods t...
In this research, we used network pharmacology and molecular docking to reveal the interaction mechanism in the glycyrrhetinic acid (GA) for the treatment of CS, and validated the effect of GA interve...
First, we screened corresponding target of GA and CS from online databases, and obtained the action target genes through the Venn diagram. Then, protein-protein interaction (PPI) network, Gene ontolog...
84 action target genes were obtained from online database. The PPI network of target genes showed that TNF, IL6, MAPK3, PTGS2, ESR1 and PPARG were considered as the core genes. The results of GO and K...
GA has a potential inhibitory effect on CS, which is worthy of further exploration....
Coronavirus Disease 2019 (COVID-19) pandemic has been on the agenda of humanity for more than 2 years. In the meantime, the pandemic has caused economic shutdowns, halt of daily lives and global mobil...
The active pursuit of network medicine for drug repurposing, particularly for combating Covid-19, has stimulated interest in the concept of structural controllability in cellular networks. We sought t...
We developed an efficient algorithm to identify all control hubs, applying it to a largest homogeneous network of human protein interactions, including interactions between human and SARS-CoV-2 protei...
Our findings confirm the efficacy of our novel strategy that leverages control hubs as drug targets. This approach provides insights into the molecular mechanisms of potential therapeutics for Covid-1...
Transmembrane protease serine 2 (TMPRSS2) has been identified as a critical key for the entry of coronaviruses into human cells by cleaving and activating the spike protein of SARS-CoV-2. To block the...
By utilizing Optum Life Sciences Claims Data, we constructed Real World Data (RWD) cohorts comprising over 3 million patients and simulated a clinical trial observational study design to evaluate over...
SARS-CoV-2 is the causative viral pathogen driving the COVID-19 pandemic that prompted an immediate global response to the development of vaccines and antiviral therapeutics. For antiviral therapeutic...
Public transport disruptions caused by the COVID-19 pandemic had wide-ranging impacts on the ability of individuals to access health care. Individuals with opioid use disorder represent an especially ...